Stryker (NYSE:SYK) Price Target Raised to $440.00 at Stifel Nicolaus

Stryker (NYSE:SYK - Get Free Report) had its price objective raised by Stifel Nicolaus from $400.00 to $440.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the medical technology company's stock. Stifel Nicolaus' target price points to a potential upside of 12.54% from the company's current price.

SYK has been the topic of several other reports. Citigroup raised their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. StockNews.com downgraded shares of Stryker from a "buy" rating to a "hold" rating in a research note on Wednesday, January 22nd. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Tuesday, January 7th. Robert W. Baird lifted their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Finally, Piper Sandler reissued an "overweight" rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $413.45.

Stryker Stock Down 1.1 %

Shares of NYSE SYK traded down $4.17 during mid-day trading on Wednesday, reaching $390.98. The company had a trading volume of 3,322,039 shares, compared to its average volume of 1,598,895. The firm has a 50 day simple moving average of $376.44 and a two-hundred day simple moving average of $361.98. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. Stryker has a 52-week low of $314.05 and a 52-week high of $406.19. The stock has a market cap of $149.05 billion, a P/E ratio of 41.91, a PEG ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same period in the prior year, the firm earned $3.46 EPS. Sell-side analysts predict that Stryker will post 12.06 earnings per share for the current year.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the business's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of Stryker

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zhang Financial LLC boosted its position in shares of Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after purchasing an additional 40,784 shares in the last quarter. Dale Q Rice Investment Management Ltd acquired a new stake in shares of Stryker in the 4th quarter worth about $587,000. Berkshire Bank lifted its position in Stryker by 13.8% in the 4th quarter. Berkshire Bank now owns 8,489 shares of the medical technology company's stock valued at $3,056,000 after acquiring an additional 1,030 shares in the last quarter. PFW Advisors LLC bought a new stake in Stryker during the 4th quarter worth approximately $1,350,000. Finally, Traynor Capital Management Inc. purchased a new stake in shares of Stryker in the fourth quarter worth approximately $324,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.